BioSyent is a profitable, growth oriented specialty pharmaceutical company that sources and markets innovative products. The company acquires the exclusive rights to patented pharmaceutical products that have already been proven to be safe and effective, and then markets and distributes them in Canada. The company focuses on products with small but very profitable addressable markets ($2-15 million peak penetration) in Canada. The company's goal is to acquire and distribute two to four new products per year, thus showing consistent profitable growth. Total sales for Q2 2014 of $3,072,395, were 72% higher compared to $1,786,684 in the corresponding prior year period. Total Sales for H1 2014 of $5,520,496 were 66% higher than H1 2013.
Pharmaceutical Sales in Q2 2014 increased by 72% from $1,683,793 in Q2 2013 to $2,893,162 in Q2 2014. Total Pharmaceutical Sales for H1 2014 of $5,236,170 were 75% higher than H1 2013.
Net Income Before Tax for Q2 2014 was $1,219,855, which was 125% higher than $542,964 in Q2 2013. Net Income Before Tax for H1 2014 was $1,907,527 or 86% higher than the corresponding prior year period.
Net Income After Tax increased by 112% from $418,325 in Q2 2013 to $888,805 in Q2 2014. Net Income After Tax for H1 2014 was $1,400,226 or 84% higher than the corresponding prior year period.
The company remains debt-free and has an unutilized operating line of credit with Royal Bank of Canada
BIOYF Security Details
|Market Value ||$115,710,000 ||a/o Aug 27, 2014 |
|Shares Outstanding ||13,800,000 ||a/o Jun 30, 2014 |